Azithromycin/dexamethasone - InSite Vision

Drug Profile

Azithromycin/dexamethasone - InSite Vision

Alternative Names: AzaSite Otic; AzaSite Plus; ISV-016; ISV-502

Latest Information Update: 13 Nov 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator InSite Vision
  • Class Anti-inflammatories; Antibacterials; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Macrolides; Pregnadienetriols
  • Mechanism of Action Glucocorticoid receptor agonists; Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Blepharitis
  • Discontinued Otitis externa; Otitis media

Most Recent Events

  • 03 Nov 2015 InSite Vision became an indirect wholly owned subsidiary of Sun Pharma
  • 03 Nov 2015 InSite Vision has been acquired by Sun Pharmaceutical Industries
  • 23 Jul 2013 InSite Vision to meet with US FDA on 19 August 2013 to discuss trial results (primary endpoint not met) for the DOUBle phase III trial in blepharitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top